Results 51 to 60 of about 316,007 (306)

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study. [PDF]

PLoS ONE, 2016
Female breast cancer patients have an increased risk of developing subsequent malignant diseases, but this issue is rarely discussed in regards to male breast cancer patients. Thus, we conducted a national survey that included 100,915 female and 578 male
Man-Hsin Hung, Chia-Jen Liu, Chung-Jen Teng, Yu-Wen Hu, Chiu-Mei Yeh, San-Chi Chen, Sheng-Hsuan Chien, Yi-Ping Hung, Cheng-Che Shen, Tzeng-Ji Chen, Cheng-Hwai Tzeng, Chun-Yu Liu   +11 more
doaj   +1 more source

Case Report: Response to Immunotherapy and Anti-Androgen Therapy in Male Occult Triple-Negative Breast Cancer

Frontiers in Oncology, 2022
Male occult triple-negative breast cancer (TNBC) is an exceedingly rare form of breast cancer, and prospective information regarding its management is therefore lacking. Current treatment strategies are largely extrapolated from clinical trials of female
Xin-Hua Wang, Jing Zhang, Jie Wu, Xiao-Han He, Yan-Ru Shen, Yong-Gang Peng, Yu-Zhi An   +6 more
doaj   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer

Breast Cancer Research, 2020
Background Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight may improve male breast cancer ...
Si-Qi Qiu, Johan van Rooijen, Hilde H. Nienhuis, Bert van der Vegt, Hetty Timmer-Bosscha, Elise van Leeuwen-Stok, Annemiek M. E. Walenkamp, Carolien H. M. van Deurzen, Geertruida H. de Bock, Elisabeth G. E. de Vries, Carolien P. Schröder   +10 more
doaj   +1 more source

Male breast cancer in Iceland [PDF]

International Journal of Cancer, 1996
All malignant tumours of the male breast diagnosed in Iceland during the 40-year period 1955-1994 were studied with regard to histological classification, tumour grading and flow cytometric analysis. Of 31 malignant tumours diagnosed, 29 were primary breast carcinomas. Male breast carcinoma constitutes 1% of all breast malignancies in Iceland and 0.25%
J G, Jonasson, B A, Agnarsson, S, Thorlacius, J E, Eyfjord, H, Tulinius   +4 more
openaire   +2 more sources

Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study.

, 2011
BACKGROUND: Genome-wide association studies have identified several common genetic variants associated with breast cancer risk. It is likely, however, that a substantial proportion of such loci have not yet been discovered.
Gibson, Lorna J, Jones, M, Tomlinson, IP, Ross, G, Lorna J. Gibson, Schoemaker, M, Lathrop, M, Ross, Gillian, Peto, Julian, Swerdlow, A, Gemma Simpson, Johnson, Nichola, Fletcher, Olivia, Coupland, Ben, Hosking, FJ, Minouk Schoemaker, Chanock, Stephen J., Williamson, Jill, Zelenika, D, Schoemaker, Minouk, Coupland, B, Fay J. Hosking, Simpson, Gemma, Palles, Claire, Gut, I, Jill Williamson, Kevin B. Jacobs, Jacobs, Kevin B, Ashworth, A, Katarzyna Tomczyk, Houlston, RS, Johnson, N, Gillian Ross, Chanock, SJ, Alan Ashworth, Swerdlow, Anthony, Hunter, DJ, Jones, Michael, Chilcott-Burns, S, Dos-Santos-Silva, Isabel, Stephen J. Chanock, Lathrop, Mark, Williamson, J, Simon Heath, Broderick, P, Sarah Chilcott-Burns, Isabel dos Santos Silva, Walker, Kate, Fletcher, O, Heath, S, dos Santos Silva, Isabel, Houlston, Richard S, Zelenika, Diana, Mark Lathrop, Tomczyk, K, Nichola Johnson, Walker, K, Ben Coupland, David J. Hunter, Claire Palles, Palles, C, Ashworth, Alan, Kate Walker, Tomczyk, Katarzyna, Tomlinson, Ian P, Simpson, G, Orr, Nick; id_orcid, Nick Orr, Peter Broderick, Orr, Nick, Orr, N, Swerdlow, Anthony J, Ivo Gut, Peto, J, Tomlinson, Ian, Michael Jones, dos Santos Silva, I, Jacobs, KB, Diana Zelenika, Ian P. Tomlinson, Gut, Ivo, Chanock, Stephen J, Broderick, Peter, Chilcott-Burns, Sarah, Olivia Fletcher, Gibson, LJ, Anthony Swerdlow, Walker-Springett, Kate, Richard S. Houlston, Hosking, Fay J, Heath, Simon, Julian Peto, Hunter, David J   +92 more
core   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Rethinking Gender and Epistemic Injustice: A Comparative Study of Male and Female Breast Cancer Memoirs

Humanities
Breast cancer patients’ experiences of epistemic injustice in healthcare is a well-established fact. However, the significant role that gender plays in deciding the nature of epistemic injustice encountered by male and female breast cancer patients is ...
Mahua Bhattacharyya, Ajit K Mishra
doaj   +1 more source

Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.

, 2007
Rare inactivating mutations in BRCA1, BRCA2, ATM, TP53 and CHEK2 confer relative risks for breast cancer between about 2 and more than 10, but more common variants in these genes are generally considered of little or no clinical significance.
dos Santos Silva, Isabel, Gibson, Lorna, Webb, Emily, Gabrielle Sellick, Lorna Gibson, Houlston, Richard, Nichola Johnson, Peto, Julian, Johnson, Nichola, Fletcher, Olivia, Claire Palles, Sean V. Tavtigian, Agnes Fraser, Rudd, Matthew, Ashworth, Alan, Isabel Dos Santos Silva, Palles, Claire, McCormack, Valerie, Tavtigian, Sean V, Leonard, Angela, Alan Ashworth, Valerie Mccormack, Gilham, Clare, Emily Webb, Richard Houlston, Sellick, Gabrielle, Olivia Fletcher, Matthew Rudd, Angela Leonard, Clare Gilham, Fraser, Agnes, Julian Peto   +31 more
core   +1 more source